Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5643_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Contents
- •1.1 Introduction
- •1.2 The Evolution of Herbal Medicine: A Historical Perspective
- •1.3 Diversity of Herbal Pharmacopoeias Across the Globe
- •1.3.1 The Indian Pharmacopoeia (IP)
- •1.3.2 The European Pharmacopoeia (Ph. Eur.)
- •1.3.3 United States Pharmacopoeia (USP)
- •1.3.4 The Russian Federation’s State Pharmacopoeia (SPRF)
- •1.3.6 Hausa Herbal Pharmacopoeia
- •1.5 Ayurveda and the Integration of Nanotechnology
- •1.6 Enhancing Herbal Medicines Through Nanotechnology
- •1.7 Approaches of Nanotechnology in Herbal Medicine
- •1.7.1 Solid Lipid Nanoparticles (SLN)
- •1.7.2 Nanoemulsions
- •1.7.3 Liposomes
- •1.7.4 Ethosomes, Transferosomes, and Transethosomes
- •1.7.5 Niosomes and Phytosomes
- •1.7.6 Micelles, Dendrimers, and Nanostructured Lipid Carriers (NLCs)
- •1.7.7 Nanoparticles, Nanocapsules, and Nanogels
- •1.8 Types of Novel Drug Delivery Systems (NDDS)
- •1.9 Nanotechnology and Its Applications
- •1.10 Efficacy and Safety of Herbal Medicine
- •1.11 Concept of Bhasma and Nanotechnology
- •1.11.1 Nanoparticle Nature of Bhasma
- •1.3.5 Romanian Pharmacopoeia (RPh)
- •1.12 Supermolecules and Nanotechnology
- •1.14 Future Prospects of Nanomedicines
- •1.15 Conclusion
- •References
- •2.1 Introduction
- •2.2 Prehistory
- •2.2.1 Ancient Civilization
- •2.2.1.1 Mesopotamia
- •2.2.1.2 Ancient Egypt
- •2.2.1.3 India, China, Greece, & Rome
- •2.2.1.3.1 India
- •2.2.1.3.2 China
- •2.2.1.3.3 Greece and Rome
- •2.3 Middle Ages and Beyond
- •2.3.1 Translation of Herbals
- •2.3.2 Early Modern Era
- •2.4 Modern Times
- •2.5 Current Status
- •2.6 Challenges Associated
- •2.6.1 Regulation and Safety of Herbal Medications
- •2.6.2 Quality Control of Herbal Medicine
- •2.6.3 Safety Monitoring of Herbal Medicines
- •2.6.4 Bioavailability of Herbal Medicines
- •2.6.5 Clinical Trials
- •2.7 Future Perspectives
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Herbal Extraction
- •3.2.2 Choice: Solvent Selection of a Suitable Medium
- •3.3 Supercritical Fluid Extraction (SFE)
- •3.3.1 Working Principle of SFE
- •3.3.2 Parts of the SFE System
- •3.3.3 Process of extraction
- •3.3.4 Applications
- •3.4 Microwave-Assisted Extraction (MAE)
- •3.4.1 Working Principle
- •3.4.2 Components of a Microwave-Assisted Extraction System
- •3.4.3 Method of Extraction from Herbs by MAE
- •3.5 Ultrasound-Assisted Extraction (UAE)
- •3.5.1 Working Principle
- •3.9.3 Applications of GC-MS in Herbal Analysis
- •3.9.4 Endowed Oil Analysis
- •3.9.5 Alkaloids and Phenolic Compounds
- •3.9.6 Terpenoids
- •3.9.7 Quantitative Analysis
- •3.9.8 Data Analysis and Interpretation
- •3.10 Liquid Chromatography-Mass Spectrometry (LC-MS)
- •3.10.1 Principles of Liquid Chromatography-Mass Spectrometry
- •3.5.1.1 Cell Disruption
- •3.5.1.2 Increased Mass Transport
- •3.5.1.3 Enhanced Solvent Effectiveness
- •3.5.2 Parts of the Ultrasound-Assisted Extraction System
- •3.5.3 Method of Extraction from Herbs
- •3.6 Pressurized Liquid Extraction (PLE)
- •3.6.1 Definition
- •3.6.2 Working Principle
- •3.6.3 Parts of the PLE System
- •3.6.4 PLE Extraction Method
- •3.7 Subcritical Water Extraction (SWE)
- •3.7.1 Supercritical fluids
- •3.7.2 Supercritical Fluid Extraction (SFE)
- •3.7.3 Working Principle of Subcritical Water Extraction (SWE)
- •3.7.4 Parts of the Subcritical Water Extraction System
- •3.7.5 Process of Subcritical Water Extraction
- •3.8 High-Performance Liquid Chromatography (HPLC)
- •3.8.1 Principles of HPLC
- •3.8.2 Bioactive Compounds Analysis
- •3.8.2.1 Phenolic Compounds
- •3.8.2.2 Alkaloids
- •3.8.2.3 Terpenoids
- •3.8.3 Recent Advances in HPLC Techniques
- •3.8.3.1 Ultra-High-Performance Liquid Chromatography
- •3.8.3.2 HPLC-MS
- •3.8.3.3 Chiral HPLC
- •3.8.4 Applications of Herbal Medicine
- •3.8.4.1 Quality Control
- •3.8.4.2 Pharmacokinetic
- •3.8.4.3 Challenges and Prospects for Further Study
- •3.9 Gas Chromatography-Mass Spectrometry (GC-MS)
- •3.9.1 Principles of GC-MS
- •3.9.2 Sample Preparation
- •3.10.2 Methods for LC-MS Detection Analysis
- •3.10.2.1 Applications of LC-MS in Herbal Analysis
- •3.10.3 Principles of FTIR
- •3.10.4 Application of FTIR in Herb Analysis
- •3.10.5 Phytochemical Identification
- •3.10.6 Quantitation of Bioactive Compounds
- •3.10.7 Structural Elucidation
- •3.10.8 Sample Preparation for FTIR Analysis
- •3.10.9 Direct Analysis
- •3.10.10 Extraction
- •3.10.11 Pellet Preparation
- •3.10.12 Thin Films
- •3.10.13 Data Analysis and Interpretation
- •3.10.14 Advantages of FTIR on Herb Analysis
- •3.10.15 Non-Destructive
- •3.10.16 Fast and Easy
- •3.10.17 Rich Information
- •3.10.18 Versatility
- •3.10.19 Cost-Effective
- •3.10.20 FTIR Limitations and Low Sensitivity
- •3.10.21 Overlapping Bands
- •3.10.22 Preparation of the Sample
- •3.10.23 Conclusion
- •3.11 Nuclear Magnetic Resonance Spectroscopy (NMR)
- •3.11.1 Sample Preparation and Instrumentation
- •3.11.2 One-Dimensional NMR Spectroscopy
- •3.11.3 Two-Dimensional NMR Spectroscopy
- •3.11.4 Phytochemical Applications
- •3.11.6 Techniques of Standardization
- •3.11.7 Extraction and Analysis of Bioactive Compounds
- •3.11.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Historical Context of Plant-Based Medicines
- •4.2.2 Development of Pharmacognosy
- •4.2.3 Impact of Plant-Based Medicines on Modern Pharmacology
- •4.3.1 Integration of Ethnobotanical Knowledge
- •4.3.2 Advanced Phytochemical Techniques
- •4.3.3 Bioassay-Guided Fractionation
- •4.3.4 Role of Metabolomics and Genomics
- •4.3.5 Integration of Nanotechnology
- •4.4 Ethnobotanical Approaches
- •4.4.1 Traditional Knowledge and Indigenous Applications
- •4.4.2 Ethnopharmacological Surveys and Their Relevance
- •4.5 Phytochemical Techniques
- •4.5.1 Methods of Plant Extraction and Isolation
- •4.5.1.1 Solvent Extraction
- •4.5.1.2 Supercritical Fluid Extraction (SFE)
- •4.5.1.3 Microwave-Assisted Extraction (MAE)
- •4.5.1.4 Ultrasound-Assisted Extraction (UAE)
- •4.5.1.5 Enzyme-Assisted Extraction (EAE)
- •4.6 Bioassay-Guided Fractionation
- •4.6.1 Fractionation Techniques
- •4.6.2 Biological Assays
- •4.6.3 Iterative Purification
- •4.7.1 High-Performance Liquid Chromatography (HPLC)
- •4.7.2 Gas Chromatography-Mass Spectrometry (GC-MS)
- •4.7.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
- •4.7.4 Fourier Transform Infrared (FTIR) Spectroscopy
- •4.7.5 Metabolomics and Genomics in Plant Drug Discovery
- •4.8 Role of Metabolomics in Identifying Bioactive Compounds
- •4.8.1 Identification of Bioactive Compounds
- •4.8.2 Explanation of Biosynthetic Pathways
- •4.8.3 Discovery of Biosynthetic Genes
- •4.8.4 Enhancement of Phytochemical Production
- •4.9 Case Studies of Genomic Applications in Drug Discovery
- •4.9.1 Case Study 1: Artemisinin Production in Artemisia annua
- •4.9.2 Case Study 2: Taxol Biosynthesis in Taxus spp.
- •4.9.3 Case Study 3: Resveratrol Production in Vitis vinifera
- •4.10 Biotechnological Advances
- •4.10.1 Tissue Culture and the Genetic Modification of Medicinal Plants
- •4.10.2 Sustainable Production of Phytochemicals through Biotechnology
- •4.10.3 Role of Synthetic Biology in Plant-Based Drug Development
- •4.11 Nanotechnology in Phytochemical Delivery
- •4.11.1 Enhancing the Bioavailability of Plant-Derived Drugs with Nanocarriers
- •4.11.1.1 Nanoparticles
- •4.11.1.2 Liposomes
- •4.11.1.3 Nanoemulsions
- •4.11.2 Targeted Delivery Systems Using Nanotechnology
- •4.11.2.1 Active Targeting
- •4.11.2.2 Passive Targeting
- •4.11.2.3 Multifunctional Nanocarriers
- •4.11.3 Case Studies of Nano-Formulated Phytochemicals
- •4.11.3.1 Curcumin-Loaded Nanoparticles
- •4.11.3.2 Quercetin-Loaded Liposomes
- •4.11.3.3 Resveratrol-Functionalized Gold Nanoparticles
- •4.11.3.4 Nanoemulsion Formulations of Essential Oils
- •4.12.1 Paclitaxel (Taxol)
- •4.12.2 Artemisinin
- •4.12.3 Morphine
- •4.12.4 Quinine
- •4.12.5 Challenges and Limitations in Plant-Based Drug Development
- •4.12.5.1 Complexity of Plant Extracts
- •4.12.5.2 Variability in Chemical Composition
- •4.12.5.3 Sustainable Sourcing and Conservation
- •4.12.5.4 Regulatory and Approval Processes
- •4.12.6 Intellectual Property and Benefit Sharing
- •4.13 Future Perspectives
- •4.13.1 Emerging Trends in Plant-Based Drug Discovery
- •4.13.2 Integrating Traditional Knowledge with Modern Science
- •4.13.3 Potential of Plant Genomics and Biotechnology
- •4.14 Conclusion
- •References
- •5.1 Introduction
- •5.2 Traditional Phytomedicine
- •5.3 Modern Phytomedicine
- •5.4 Synthesis and Purpose of Bioactive Compounds
- •5.5.1 Phenolic Compounds (PCs)
- •5.5.2 Terpenes
- •5.5.3 Nitrogen-Containing Compounds
- •5.6 Extraction of Bioactive Compounds
- •5.7 Role of Herbs in Drug Discovery
- •5.8 Global Trade of Herbal Medicines
- •5.9.1 Herbal Compounds for the Human Immune System
- •5.9.2 Bioactive Compounds in Herbs For Cancer Treatment
- •5.9.3 Bioactive Compounds for Neurodegenerative Diseases
- •5.9.4 Bioactive Compounds for Viral Diseases
- •5.9.5 Anti-Inflammatory Bioactive Compounds in Herbs
- •5.9.6 Antidiabetic Bioactive Compounds in Herbs
- •5.9.7 Antibiotics
- •5.10 Summary
- •References
- •6.1 Introduction
- •6.1.2 Antibiotic-Resistant Microorganisms
- •6.1.3 Necessity of Developing Natural Plant-Derived Drugs
- •6.2 Pharmacological Activities of Medicinal Plants
- •6.2.1 Antimicrobial Activity of Herbal Drugs
- •6.2.2 Anticancer Activity of Medicinal Herbs
- •6.2.3 Antiviral Activity of Medicinal Herbs
- •6.2.3.1 Medicinal Plants Exhibiting Antiviral Activity
- •6.2.4 Antioxidant Activity of Medicinal Herbs
- •6.2.5 Hepatoprotective Activity of Medicinal Herbs
- •6.2.6 Nervous System Activity of Medicinal Herbs
- •6.2.7 Anti-Inflammatory Activity of Medicinal Herbs
- •6.2.7.1 Mechanism of Action
- •6.2.8 Antipyretic Activity of Medicinal Herbs
- •6.2.8.1 Medicinal Plants Possessing Antipyretic Properties
- •6.2.9 Antiallergic Activity of Medicinal Herbs
- •6.2.10 Antidiabetic Activity of Medicinal Herbs
- •6.2.10.1 Medicinal Plants Possessing Antidiabetic Activity
- •6.2.11 Immunomodulatory Activity of Medicinal Herbs
- •6.3 Advantages of Medicinal Herbs
- •6.4 Disadvantages of Medicinal Herbs
- •6.5 Future Prospects of Medicinal Herbs
- •References
- •7.1 Introduction to Herbal Drug Discovery
- •7.1.1 History of Herbal Drug Discovery
- •7.2 Current trends in herbal drug discovery
- •7.2.1 Molecular and Genetic Study Levels
- •7.2.2 Molecular Pharmacognosy
- •7.2.3 Combination Therapy
- •7.2.4 Conservation and Propagation Strategies
- •7.2.5 Pharmacogenomics
- •7.2.6 Computational Resources for Drug Discovery
- •7.4.1 Metabolomics Approaches in Herbal Drug Discovery
- •7.4.2 Genomic Approaches
- •7.5.1 Quinine for Malarial Treatment
- •7.5.2 Aspirin for Pain and the Treatment of Inflammation
- •7.6 Limitations in Herbal Drug Discovery
- •7.6.1 Regulatory Hurdles
- •7.6.2 Emerging Technologies
- •References
- •8.1 Introduction
- •8.2 Traditional Approaches to Herbal Formulation
- •8.3 Phytochemical Constituents in Herbal Formulations
- •8.3.1 Alkaloids
- •8.3.2 Flavonoids
- •8.3.3 Terpenoids
- •8.3.4 Glycosides
- •8.3.5 Tannins
- •8.3.6 Phenolic Acids
- •8.3.7 Saponins
- •8.4 Modern Extraction Techniques in Herbal Formulation
- •8.4.1 Solvent Extraction
- •8.4.2 Supercritical Fluid Extraction (SFE)
- •8.4.3 Ultrasonic Extraction
- •8.4.4 Microwave-Assisted Extraction (MAE)
- •8.4.5 Enzyme-Assisted Extraction (EAE)
- •8.4.6 Comparative Analysis of Extraction Techniques
- •8.5 Advanced Formulation Strategies
- •8.5.1 Nanotechnology in Herbal Formulations
- •8.5.1.1 Nanoemulsions
- •8.5.1.2 Liposomes
- •8.5.1.3 Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)
- •8.5.2 Encapsulation Techniques
- •8.5.2.1 Microencapsulation
- •8.5.2.2 Coacervation
- •8.5.2.3 Spray Drying
- •8.5.3 Standardized Extracts
- •8.5.3.1 Methods of Standardization
- •8.5.3.2 Challenges in Standardization
- •8.5.4 Synergistic Formulations
- •8.5.4.1 Mechanisms of Synergy
- •8.5.4.2 Examples of Synergistic Formulations
- •8.5.5 Personalized Herbal Formulations
- •8.5.5.1 Role of Genomics in Personalized Herbal Medicine
- •8.5.5.2 Challenges in Personalized Herbal Formulations
- •8.6.1 Recognition and Verification of Herbal Materials
- •8.6.1.4 DNA Barcoding
- •8.6.2 Use of Reference Standards
- •8.6.2.1 Primary and Secondary Reference Standards
- •8.6.2.2 Development of Reference Standards
- •8.6.3 Good Manufacturing Practices (GMP)
- •8.6.3.1 Sourcing and Handling of Raw Materials
- •8.6.3.2 Manufacturing Processes
- •8.6.3.3 Quality Control Testing
- •8.6.3.4 Documentation and Record-Keeping
- •8.7 Challenges in Herbal Formulation Development
- •8.7.1 Variability in Chemical Composition
- •8.7.1.1 Factors Affecting Chemical Composition
- •8.7.1.2 Strategies to Address Variability
- •8.7.2 Complexity of Herbal Extracts
- •8.7.2.1 Analytical Challenges
- •8.7.2.2 Formulation Challenges
- •8.7.3 Standardization of Herbal Formulations
- •8.7.3.1 Challenges in Standardization
- •8.7.3.2 Advances in Standardization
- •8.7.4 Regulatory Hurdles
- •8.7.4.1 Regulatory Requirements
- •8.7.4.2 Challenges in Meeting Regulatory Requirements
- •8.7.4.3 Strategies to Overcome Regulatory Hurdles
- •8.8 Future Directions in Herbal Formulation Development
- •8.8.1 Artificial Intelligence and Machine Learning
- •8.8.1.1 Applications in Herbal Formulation Development
- •8.8.1.2 Challenges and Opportunities
- •8.8.2 Integration of Omics Technologies
- •8.8.2.1 Applications in Herbal Medicine
- •8.8.2.2 Challenges and Opportunities
- •8.8.3 Novel Delivery Systems
- •8.8.3.1 Nanotechnology in Herbal Medicine
- •8.8.3.2 Other Novel Delivery Systems
- •8.8.3.3 Challenges and Opportunities
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Herbal Nanotechnology and Phytonanomedicines
- •9.2.1 Role of Phytonanomedicines in Disease Management
- •9.2.1.1 Cancer
- •9.2.1.2 Diabetes Mellitus
- •9.2.1.3 Neurodegenerative Diseases (NDDs)
- •9.2.1.4 Cardiovascular Diseases (CVD)
- •9.3 Nanoparticles for Plant Disease Management
- •9.3.1 Role of Silver Nanoparticles (AgNPs) in Plant Disease Management
- •9.3.2 Role of Gold Nanoparticles (AuNPs) in Plant Disease Management
- •9.3.3 Role of Zinc Nanoparticles (ZnNPs) in Plant Disease Management
- •9.3.4 Role of Palladium Nanoparticles (PdNPs) in Plant Disease Management
- •9.3.5 Role of Titanium Nanoparticles (TiNPs) in Plant Disease Management
- •9.3.6 Role of Iron Nanoparticles (FeNPs) in Plant Disease Management
- •9.3.7 Role of Copper Nanoparticles (CuNPs) in Plant Disease Management
- •9.3.8 Role of Selenium Nanoparticles (SeNPs) in Plant Disease Management
- •9.4 Nanoparticles as Carriers
- •9.4.1 Nanoparticles as Carriers for Insecticides
- •9.4.2 Nanoparticles as Carriers for Fungicides
- •9.4.3 Nanoparticles as Carriers for Herbicides
- •9.4.4 Role of Nanoparticles and RNAi in Plant Disease Management
- •References
- •10.1 Introduction
- •10.2 Types of Nanomaterials Utilized in Herbal Pharmaceuticals
- •10.2.1 Nanoparticles
- •10.2.2 Nanocapsules
- •10.2.3 Nanospheres
- •10.2.4 Nanotubes
- •10.3 Innovative Applications of Nanotechnology
- •10.3.1 Anti-Cancer Herbal Nanomedicine
- •10.3.2 Anti-Inflammatory Herbal Nanomedicine
- •10.3.3 Antibacterial Herbal Nanomedicine
- •10.3.4 Antifungal Herbal Nanomedicine
- •10.3.5 Antioxidant Neuroprotective Herbal Nanomedicine
- •10.3.6 Anti-Diabetic Herbal Nanomedicine
- •10.3.7 Cardioprotective Herbal Nanomedicine
- •10.4.1 Combining Nanotechnology and Herbal Pharmacotherapy
- •10.4.2 Enhanced Bioavailability
- •10.4.3 Targeted Delivery
- •10.4.4 Improved Stability or Shelf Life
- •10.4.5 Synergistic Effects and Combination Therapies
- •10.4.6 Reduced Dosage and Toxicity
- •10.4.7 Crossing Biological Barriers
- •10.5 Challenges and Limitations
- •10.5.1 Complexity of Herbal Systems
- •10.5.2 Bioavailability Enhancement
- •10.5.3 Regulatory and Ethical Considerations
- •10.5.4 Cost and Scalability
- •10.5.5 Safety and Toxicity Issues
- •10.5.6 Standardization and Quality Control
- •10.6 Future Prospects and Trends
- •10.7 Conclusion
- •References
- •11. Nanoparticle Synthesis and Characterization for Herbal Drug Delivery
- •11.1 Introductions
- •11.2 Background and Literature Review
- •11.2.1 Historical Overview and Present Trends in Herbal Medicine
- •11.2.2 Overview of Nanoparticles in Drug Delivery
- •11.2.3 Advantages of Nanoparticle-Based Drug Delivery Systems
- •11.3.1 Polymer Nanoparticle
- •11.3.2 Metallic Nanoparticles
- •11.3.3 Magnetic Nanoparticles
- •11.3.4 Liposomes
- •11.3.5 Dendrimers
- •11.3.6 Niosomes
- •11.3.7 Proniosomes
- •11.3.8 Phytosomes
- •11.3.9 Transfersomes
- •11.3.10 Microspheres
- •11.3.11 Ethosomes
- •11.4 Nanoparticle Synthesis Techniques
- •11.4.1 Top-Down Approach
- •11.4.2 Bottom-Up Approach
- •11.4.3 Chemical Methods
- •11.4.3.1 Sol-Gel Method
- •11.4.3.2 Spinning
- •11.4.3.3 Microemulsion Technique
- •11.4.3.4 Hydrothermal Synthesis
- •11.4.3.5 Electrochemical Synthesis
- •11.4.3.6 Polyol Synthesis
- •11.4.3.7 Thermal Decomposition
- •11.4.3.8 Chemical Vapor Deposition & Chemical Vapor Synthesis
- •11.4.3.9 Plasma-Enhanced Chemical Vapor Deposition
- •11.4.4 Physical Methods
- •11.4.4.1 High-Energy Ball Milling Process
- •11.4.4.2 Physical Vapor Deposition (PVD)
- •11.4.4.3 Pyrolysis
- •11.4.4.4 Melt Mixing
- •11.4.4.5 Laser Ablation (LA) and Pulse Laser Deposition (PLD)
- •11.4.4.6 Electron Beam Evaporation (EBE)
- •11.4.4.7 Inert Gas Condensation (IGC)
- •11.4.4.8 Flame Spray Pyrolysis (FSP)
- •11.4.4.9 Laser Pyrolysis
- •11.4.4.10 Nanolithography
- •11.4.4.11 Electrospraying Technique
- •11.4.5 Biosynthesis of Nanoparticles
- •11.4.5.1 Utilizing Biomolecules as Templates for Synthesis
- •11.4.5.2 Microbial Synthesis
- •11.4.5.3 Utilizing Botanical Extracts for Synthesis
- •11.4.6 Mechanical Techniques
- •11.5 Characterization of Nanoparticles
- •11.5.1 Chemical
- •11.5.2 Physical
- •11.5.2.1 Particle Size Analyzer
- •11.5.2.2 Surface Area Analysis
- •11.5.2.3 Zeta Potential
- •11.5.2.4 Thermogravimetric Analysis (TGA)
- •11.5.2.5 Dynamic Light Scattering
- •11.5.2.6 Scanning Electron Microscopy (SEM)
- •11.5.2.7 Nuclear Magnetic Resonance
- •11.5.2.8 Transmission Electron Microscopy (TEM)
- •11.5.2.9 X-Ray Powder Diffraction (XRD)
- •11.5.2.10 Evaluation of Recovery and Encapsulation Performance
- •11.5.2.11 Atomic Force Microscopy
- •11.5.2.12 UV-Visble Spectroscopy
- •11.5.2.13 Surface Plasmon Resonance
- •11.5.2.14 Acoustic Methods
- •11.6 Conclusion
- •References
- •12.1 Introduction
- •12.1.1 Challenges of Herbal Extracts in Traditional Medicine
- •12.1.2 Importance of Bioavailability in Therapeutic Efficacy
- •12.1.3 The Role of Nanotechnology in Addressing Bioavailability Issues
- •12.2 Principles of Bioavailability Enhancement
- •12.2.1 Understanding ADME Profiles
- •12.2.1.1 Absorption
- •12.2.1.1.1 Distribution
- •12.2.1.1.2 Metabolism
- •12.2.1.1.3 Excretion
- •12.2.2 Factors Affecting the Bioavailability of Herbal Compounds
- •12.2.2.1 Absorption within the GI Lumen
- •12.2.2.1.1 The Solubility of the Herbal Products
- •12.2.2.1.2 Absorption via Passive Diffusion
- •12.2.2.2 Metabolism
- •12.2.2.2.1 Metabolism Prior to Absorption
- •12.2.2.2.2 Metabolism Post-Absorption
- •12.2.2.3 Mechanisms of Action for Nanocarriers
- •12.3 Types of Nanocarriers and Their Applications
- •12.3.1 Liposomes: Structure, Function, and Applications
- •12.3.1.1 Structure
- •12.3.1.2 Function
- •12.3.1.3 Applications
- •12.3.2 Polymeric Nanoparticles: Design and Delivery Mechanisms
- •12.3.2.1 Design
- •12.3.2.1.1 Polymeric Material
- •12.3.2.1.2 Drug Encapsulation Methods
- •12.3.2.1.2.1 Solvent Evaporation
- •12.3.2.2 The Delivery Mechanism of the Drug
- •12.3.2.2.1 Route of Delivery
- •12.3.2.2.2 Targeting Strategies
- •12.3.2.2.2.1 Passive Targeting
- •12.3.2.2.2.2 Active Targeting
- •12.3.2.2.2.3 Stimuli-Responsive Targeting
- •12.3.2.2.3 Drug Release
- •12.3.2.2.3.1 Diffusion-Controlled Release
- •12.3.2.2.3.2 Solvent-Controlled Release
- •12.3.2.2.3.3 Chemical Interaction-Based Release
- •12.3.2.2.3.4 Temperature-Controlled Release
- •12.3.3 Nanoemulsions: Formulation and Stability
- •12.3.3.1 Formulation
- •12.3.3.1.1 The Generation of Nanoemulsion
- •12.3.3.2 Stability
- •12.3.3.2.1 Physical Stability
- •12.3.3.2.2 Chemical Stability
- •12.3.4 Micelles: Enhancing Solubility and Bioavailability
- •12.3.4.1 Enhancing Solubility and Bioavailability
- •12.3.4.1.1 Micellar Solubilization
- •12.3.4.1.2 Polymeric Micellar Nanocarriers
- •12.4 Nanocarriers and Solubility Enhancement
- •12.4.1 Techniques for Improving the Solubility of Hydrophobic Compounds
- •12.4.1.1 Lipid Dispersion Techniques
- •12.5 Stability of Herbal Extracts in Nanocarrier Systems
- •12.5.1 Protection against Degradation and Oxidation
- •12.5.2 Example of Stability Improvement in Herbal Extracts
- •12.5.2.2 Example 2: Enhancing Curcumin Stability and Bioavailability using SLNs
- •12.6 Targeted Delivery and Controlled Release
- •12.6.1 Key Principles
- •12.6.1.2 Design and Composition of Nanocarriers
- •12.6.1.2.1 Integration and Optimization
- •12.6.1.2.2 Advantages of Controlled Release Systems
- •12.6.1.2.3 Applications in Medicine
- •12.7 Pharmacokinetics and Pharmacodynamics
- •12.7.1 Enhancing Therapeutic Efficacy through Pharmacokinetic Modulation
- •12.7.1.1 Sustained Release and Targeted Delivery
- •12.7.1.2 Improved Bioavailability and Reduced Inter-Individual Variability
- •12.7.1.3 Enhanced Pharmacodynamic Effects
- •12.7.1.4 Reduced Adverse Effects and Toxicity
- •12.7.1.5 Opportunities for Personalized Medicine
- •12.7.2 Clinical Implications of Improved Pharmacodynamics
- •12.8 Clinical Applications and Case Studies
- •12.8.1 Successful Implementations of Nanocarrier-Based Herbal Drugs
- •12.8.1.1 Curcumin-Loaded Nanoparticles
- •12.8.1.2 Quercetin-Loaded Liposomes
- •12.8.1.3 Ginger Extract Nanocarriers
- •12.8.1.4 Green Tea Extract Nanocarriers
- •12.8.2 Challenges and Limitations in Clinical Settings
- •12.8.2.1 Quality Control and Standardization
- •12.8.2.2 Limited Encapsulation Capacity
- •12.8.2.3 Pharmacokinetic and Pharmacodynamic Variability
- •12.8.2.4 Manufacturing Challenges
- •12.9 Future Perspectives
- •12.9.1 Advancing Nanocarrier Design and Engineering
- •12.9.2 Expanding the Diversity of Herbal Extracts Formulated with Nanocarriers
- •12.9.3 Advancing Preclinical and Clinical Evaluation
- •12.9.4 Addressing Regulatory and Commercialization Challenges
- •12.9.5 Exploring Synergies with Other Emerging Technologies
- •12.10.1 Opportunities
- •12.10.2 Challenges
- •12.11 Conclusion
- •References
- •13.1 Introduction to Herbal Medicine and Neurological Diseases
- •13.1.1 Overview of Herbal Medicine
- •13.1.1.1 Key Aspects of Herbal Medicine
- •13.1.2 Scope of Neurological Diseases
- •13.1.3 Rationale for Exploring Herbal Remedies
- •13.2 Neuroprotective Effects of Herbal Compounds
- •13.2.1 Mechanisms of Neuroprotection
- •13.2.1.1 Antioxidant Activity
- •13.2.1.3 Inhibition of Excitotoxicity
- •13.2.1.4 Enhancement of Neurogenesis and Synaptic Plasticity
- •13.2.1.5 Mitochondrial Protection
- •13.2.2 Role of Oxidative Stress in Neurological Diseases
- •13.2.2.1 Essential Components of Oxidative Stress in Neurological Disorders
- •13.2.2.1.1 Impaired Functioning of Mitochondria
- •13.2.2.1.2 Neurological Disorders Linked to Oxidative Stress
- •13.2.3 Anti-Inflammatory Properties of Herbal Compounds
- •13.2.3.2 Uses and Advantages
- •13.2.4 Regulation of Neuronal Apoptosis by Herbal Remedies
- •13.2.4.1 Neurological Diseases Applications
- •13.2.4.2 Future Scope and Challenges of Therapy
- •13.3.1 Importance of Neurogenesis in Brain Repair
- •13.3.2 Effects of Herbal Extracts on Neurogenesis
- •13.3.3 Enhancement of Synaptic Plasticity by Herbal Compounds
- •13.4 Herbal Medicine as Adjunctive Therapy
- •13.4.1 Synergistic Effects of Herbal Compounds with Conventional Treatments
- •13.4.1.1 Cancer Care
- •13.4.1.2 Depression Relief
- •13.4.1.3 Heart Health
- •13.4.1.4 Diabetes Management
- •13.4.1.5 Pain Relief
- •13.4.2 Mitigation of Drug-Induced Side Effects
- •13.4.2.1 Digestive Challenges
- •13.4.2.2 Liver Safeguarding
- •13.4.2.3 Kidney Protection
- •13.4.2.4 Neurotoxicity
- •13.4.2.5 Cardiotoxicity
- •13.4.2.6 Bone Marrow Suppression
- •13.4.2.7 Managing Fatigue
- •13.4.3 Enhancement of Therapeutic Outcomes
- •13.5 Future Directions and Challenges
- •13.5.1 Opportunities for Further Research
- •13.5.2 Challenges in Herbal Medicine Research
- •13.5.3 Integration of Traditional Knowledge with Modern Science
- •13.6 Case Studies and Clinical Applications
- •13.6.1 Illustrative Case Studies
- •13.6.2 Clinical Applications of Herbal Medicine in Neurological Diseases
- •13.7 Conclusion
- •13.7.1 Summary of Key Findings
- •13.7.2 Future Outlook for Herbal Medicine in Neurology
- •References
- •14.1 Introduction
- •14.1.2.1 Physiochemical Characteristics and Biological Interactions
- •14.1.2.2 Potential Toxicity Concerns
- •14.1.2.3 Regulatory and Ethical Considerations
- •14.2 Preclinical Safety Assessment
- •14.2.1 In vitro Toxicity Testing
- •14.2.2 In vivo Animal Studies
- •14.2.3 Evaluating the Pharmacokinetics and Biodistribution of Nanoparticles
- •14.2.4 Immunogenicity and Biocompatibility Testing
- •14.3 Toxicological Profiling
- •14.3.1 Identification and Characterization of Possible Toxins
- •14.3.1.1 Nanoparticle Components
- •14.3.1.2 Contaminants and Impurities
- •14.3.1.3 Herbal Compounds
- •14.3.2 Dose–Response Relationships
- •14.4 Chronic Toxicity and Carcinogenicity Studies
- •14.4.1 Genotoxicity and Mutagenicity Testing
- •14.5 Clinical Safety Assessment
- •14.5.1 Phases of Clinical Trials for Nanoparticle-Based Herbal Formulation
- •14.5.2 Monitoring Adverse Effects and Long-Term Safety in Human Subjects
- •14.5.2.1 Initial Reporting Systems
- •14.5.2.2 Clinical Monitoring
- •14.5.2.3 Pharmacovigilance Networks
- •14.5.2.4 Regular Safety Updates
- •14.5.2.5 Post-Marketing Studies
- •14.5.2.6 Pharmacogenomics Studies
- •14.5.3 Post-Market Surveillance and Pharmacovigilance
- •14.5.3.1 Real-World Evidence Collection
- •14.5.3.2 Active Surveillance Programs
- •14.5.3.3 Signal Detection
- •14.5.3.4 Risk Communication
- •14.5.3.5 Regulatory Actions
- •14.6 Analytical Techniques for Safety Assessment
- •14.6.1 Advanced Imaging and Spectroscopy Methods
- •14.6.1.1 Transmission Electron Microscopy (TEM)
- •14.6.1.2 Scanning Electron Microscopy (SEM)
- •14.6.1.3 Infrared Spectroscopy (IRS)
- •14.6.2 Nanoparticle Tracking and Quantification
- •14.6.2.1 Nanoparticle Tracking Analysis (NTA)
- •14.6.2.2 Dynamic Light Scattering (DLS)
- •14.6.3 Surface Characterization and Stability Analysis
- •14.6.3.1 X-Ray Photoelectron Spectroscopy (XPS)
- •14.6.3.2 Differential Scanning Calorimetry (DSC)
- •14.6.4 High-Throughput Screening Technologies
- •14.6.4.1 Cell-Based Assay
- •14.6.4.2 Genotoxicity Screening
- •14.7 Regulatory Frameworks and Guidelines
- •14.7.1 International and National Regulatory Frameworks
- •14.7.1.1 Regulation Management
- •14.7.1.2 Risk Analysis
- •14.7.1.3 Labelling and Informed Consent
- •14.7.1.4 International Standards
- •14.7.1.5 Regulation in Research and Development
- •14.7.2 Risk Assessment Models and Safety Thresholds
- •14.7.2.1 Invitro Toxicity Assay
- •14.7.2.2 Green Algorithms
- •14.7.2.3 Nanoprobes for Measuring ROS
- •14.8 Risk Mitigation Strategies
- •14.8.1 Designing Safer Nanoparticle-Based Formulations
- •14.8.2 Controlled Release Systems and Targeted Delivery
- •14.8.3 Reducing Off-Target Effects and Enhancing Selectivity
- •14.8.3.1 Nanoparticle-Based Systems for Intracellular Targeting
- •14.8.4 Engineering Biodegradable and Biocompatible Nanoparticles
- •14.9 Case Studies of Safety Assessment
- •14.9.1 Successful Examples of Safe Nanoparticle-based Herbal Formulations
- •14.9.1.1 Curcumin-Loaded Nanoparticles
- •14.9.1.2 Green Tea Polyphenol (EGCG) Nanoparticles
- •14.9.2 Lessons Learned from Safety Failures and Recalls
- •14.10 Ethical Considerations
- •14.10.1 Ethical Issues in Nanotoxicology Research
- •14.10.2 Informed Consent and Patient Safety in Clinical Trials
- •14.11 Conclusion
- •References
- •15. Novel Drug Delivery Methods for Herbal Medicine
- •15.1 Introduction
- •15.2 Novel Drug Delivery Approaches
- •15.3 Potential of Novel Drug Delivery for Herbal Drugs
- •15.4 Types of Novel Herbal Drug Delivery Systems
- •15.4.1 Mouth-Dissolving Tablets
- •15.4.2 Controlled-Release Formulations
- •15.4.3 Liposomes
- •15.4.4 Phytosomes
- •15.4.5 Nanoparticles
- •15.4.6 Niosomes
- •15.4.7 Proniosomes
- •15.4.8 Transdermal Drug Delivery System
- •15.4.9 Microspheres
- •15.4.10 Emulsions
- •15.4.11 Ethosomes
- •15.4.12 Other Novel Approaches
- •15.5 Future Opportunities and Challenges
- •15.6 Conclusion
- •References
- •16.1 Fundamentals of Herbal Drug Delivery Systems
- •16.1.1 Advantages of Herbal Drugs
- •16.1.2 Challenges of Herbal Drugs
- •16.1.3 Rise of Targeted Delivery for Herbal Drugs
- •16.2 Carriers Systems for Targeted Drugs
- •16.2.1 Liposome-Mediated Drug Delivery System
- •16.2.2 Polymeric Nanoparticles as Drug Carriers
- •16.2.3 Micelles
- •16.2.4 Dendrimers
- •16.2.5 Carbon Nanotubes and Fullerenes
- •16.2.6 Phytosomes
- •16.2.7 DNA Nanocarriers for Targeted Drug Delivery
- •16.2.8 Aptamers for Drug Targeting
- •16.2.9 Microspheres and Micropellets
- •16.3 Targeting Strategies and Mechanisms
- •16.3.1 Ligand-Receptor Mediated Targeting
- •16.3.2 Antibody Drug Conjugates
- •16.3.3 Aptamers for a Targeted Delivery System for Herbal Drugs
- •16.3.4 Stimuli-Responsive Delivery Systems
- •16.4.1 Herbal Drugs for Communicable Diseases
- •16.4.2 Herbal Drugs for Communicable and Non-Communicable Diseases
- •16.5 Conclusion and Future Perspective
- •References
- •17.1 Introduction
- •17.2 An Overview of Phytomedicine
- •17.3 Application of Nanoformulation
- •17.3.1 Nanosuspension Technology
- •17.3.2 Nano-Encapsulation
- •17.3.3 Three-Dimensional Printing in Nanopharmacy (Nano Printing)
- •17.3.4 Applications in Drug Delivery Systems
- •17.3.5 Biomimetics and Bioinspiration in Nanopharmaceuticals/Nanomedicines
- •17.3.6 Green Design
- •17.4 Future study
- •17.5 Conclusion
- •References
- •18.1 Introduction
- •18.2 Herbal Phytoconstituents for Disease Management
- •18.3 Barriers to Herbal Formulations
- •18.4 Strategies to Enhance Bioavailability
- •18.5 Herbal Formulations – Conventional Dosage Forms
- •18.6 Nanocarriers in Herbal Drug Delivery
- •18.7 Clinical Status of Current Delivery Strategies
- •18.8 Conclusion
- •References
- •19.1 Introduction
- •19.1.1 Definition and Scope
- •19.1.2 History
- •19.1.3 Importance and Relevance in Modern Medicine
- •19.2 Basics of Nanotechnology and Herbal Medicines
- •19.2.1 Nanotechnology
- •19.2.2 Basics of Herbal Medicines
- •19.3 Implementing Herbal Nanomedicines
- •19.3.1 Protocols for Implementation
- •19.3.1.1 Techniques for the Preparation of Herbal Nanoparticles
- •19.3.1.2 Dosage and Administration Strategies
- •19.3.2 Documenting Patient Case Histories and its Analysis
- •19.3.2.1.1 Condition Treated
- •19.3.2.1.2 Treatment Provided
- •19.3.2.1.3 Patient Response
- •19.4 Standardized Treatment Procedures
- •19.4.1 Customization for Specific Ailments
- •19.4.2 Tailoring for Individual Patient Needs
- •19.5 Advantages of Herbal Nanomedicine in Clinical Settings
- •19.5.1 Increased Patient Adherence
- •19.5.2 Reduced Side Effects
- •19.5.3 Improved Efficacy
- •19.6 The Future of Herbal Nanomedicine in Clinical Practice
- •References
- •20.1 Herbal Nanomedicines: A Brief Overview
- •20.2 Safety Issues and Toxicological Concerns with Herbal Nanomedicines
- •20.3.1 In Vitro Methods
- •20.3.2 In Vivo Assays
- •20.3.3 Utilization of Advanced Analytical Tools
- •20.3.4 In Silico Approach: Nano-QSAR
- •20.3.5 Grouping/Read-Across Technique
- •20.3.6 Genetic Approaches
- •20.3.7 Utilization of Validated Human Cell Lines in Immunotoxicity Assays
- •20.3.8 In Vitro Carcinogenicity Assessment with Transformed Cells
- •20.3.9 DNA Barcoding
- •20.3.10 Systems Toxicology: ‘Omics’ Technology
- •20.3.11 Nano-Informatics Database
- •20.3.12 Miscellaneous Advanced Approaches in Nanotoxicology Assessment
- •20.7 Conclusion
- •Acknowledgement
- •References
- •21.1 Introduction
- •21.2 Global Regulatory Landscape
- •21.3 Regulatory Agencies and Their Roles
- •21.3.1 United States
- •21.3.1.1 Key Responsibilities of the FDA
- •21.3.2 Canada
- •21.3.3 Europe
- •21.3.3.1 European Medicine Agency
- •21.3.3.2 Key Responsibilities of the European Medicine Agency
- •21.3.3.3 Quality Guidelines of the European Medicine Agency
- •21.3.3.3.1 The Declaration of Herbal Preparations in Traditional Herbal Medicinal Products
- •21.3.3.3.2 Practices for Materials Collection from Herbal Origin
- •21.3.4 Non-Clinical Guidelines
- •21.3.4.1 Genotoxicity Assessment of Herbal Preparations
- •21.3.5 Asia
- •21.3.5.1 Traditional Chinese Medicines
- •21.3.5.2 Regulatory Approaches for TM/CM
- •21.3.6 Indian Ayurvedic Regulations
- •21.3.6.1 Food Safety and Standards Authority of India
- •21.3.7 World Health Organization
- •21.3.7.1 WHO Guidelines on the Safety Monitoring of Herbal Medicines
- •21.4 Classification of Herbal Products
- •21.4.1 Dietary Supplements
- •21.4.2 Herbal Supplements
- •21.4.3 Functional Food
- •21.4.4 Traditional Medicine
- •21.5 Approval Process
- •21.5.1 Pre-Market Approval
- •21.5.2 Post-Market Surveillance
- •21.5.3 Clinical Trials
- •21.6 Diverse Regulatory Standards
- •21.6.1 Example of Divergence
- •21.7 Efforts for International Collaboration
- •21.8 Impact of Scientific Advancements
- •21.8.1 Combination of Modern Research and Traditional Knowledge
- •21.8.2 Recognizing the Value of Traditional Knowledge
- •21.9 Approaches to Integration
- •21.9.1 Collaborative Research
- •21.9.2 Participatory Research
- •21.9.3 Interdisciplinary Research
- •21.9.4 Comparative Research
- •21.10 Challenges & Considerations
- •21.11 Advanced Technologies in Quality Control
- •21.11.1 Analytical Techniques
- •21.11.2 Good Manufacturing Practices (GMP)
- •21.11.3 Biological Assays
- •21.11.4 Standardization of Extraction Methods
- •21.11.5 Data Management & Traceability
- •21.12 Challenges & Future Directions
- •21.13 Personalized Herbal Medicine
- •21.14 Regulatory Implications
- •21.15 Sustainable and Ethical Sourcing
- •21.16 Conclusion
- •21.17 Future Outlook for the Regulatory Framework
- •References
- •22. Present Challenges and Future Perspective of the Herbal Drug Industry
- •22.1 Introduction
- •22.2 Emerging Trends and Innovations
- •22.2.1 Biotechnology and Genetic Engineering
- •22.2.2 Nanotechnology
- •22.3 Regulatory Challenges and Opportunities
- •22.4 Intellectual Property Rights
- •22.4.1 Conventional Medicine and Rights to Intellectual Property
- •22.5 Global Market Trends
- •22.6 Challenges and Limitations
- •22.7 Future Directions
- •22.8 Conclusions
- •References
- •Index

284 Herbal Pharmacopeia
51. Gogate PR, Kabadi AM. A review of applications of cavitation in biochemical engineering/biotechnol-
ogy. Biochemical Engineering Journal. 2009;44(1):60–72.
52. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano- emulsion formulation using spontaneous emulsication:
Solvent, oil and surfactant optimisation. International Journal of Pharmaceutics. 2004;280(1–2):241–51.
53. Zeeb B, Herz E, McClements DJ, Weiss J. Impact of alcohols on the formation and stability of protein-
stabilized nanoemulsions. Journal of Colloid and Interface Science. 2014;433:196–203.
54. Guan Y, Wu J, Zhong Q. Eugenol improves physical and chemical stabilities of nanoemulsions loaded
with β-carotene. Food Chemistry. 2016;194:787–96.
55. McClements DJ. Nanoemulsion- based oral delivery systems for lipophilic bioactive components:
Nutraceuticals and pharmaceuticals. Therapeutic Delivery. 2013;4(7):841–57.
56. Lee SJ, Choi SJ, Li Y, Decker EA, McClements DJ. Protein- stabilized nanoemulsions and emulsions:
Comparison of physicochemical stability, lipid oxidation, and lipase digestibility. Journal of Agricultural
and Food Chemistry. 2011;59(1):415–27.
57. Qian C, Decker EA, Xiao H, McClements DJ. Physical and chemical stability of β-carotene- enriched nanoemul-
sions: Inuence of pH, ionic strength, temperature, and emulsier type. Food Chemistry. 2012;132(3):1221–9.
58. Milovanovic M, Arsenijevic A, Milovanovic J, Kanjevac T, Arsenijevic N. Nanoparticles in Antiviral
Therapy. Elsevier; 2017. p. 383–410.
59. Bose A, Roy Burman D, Sikdar B, Patra P. Nanomicelles: Types, properties and applications in drug
delivery. IET Nanobiotechnology. 2021;15(1):19–27.
60. Kazunori K, Glenn S K, Masayuki Y, Teruo O, Yasuhisa S. Block copolymer micelles as vehicles for drug
delivery. Journal of Controlled Release. 1993;24(1–3):119–32.
61. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classi-
cation: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical
Research. 1995;12(3):413–20.
62. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to
address low drug solubility in discovery and development. Pharmacological Reviews. 2013;65(1):315–499.
63. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly
aqueous soluble drugs and therapeutics. Biomedicines. 2022;10(9):2055.
64. Chandel AKS, Nutan B, Raval IH, Jewrajka SK. Self- Assembly of Partially Alkylated Dextran- graft-
poly[(2-dimethylamino)ethyl methacrylate] Copolymer Facilitating Hydrophobic/Hydrophilic Drug
Delivery and Improving Conetwork Hydrogel Properties. Biomacromolecules. 2018;19(4):1142–53.
65. Chandel AKS, Bhingradiya N. Therapeutic efcacy of herbal formulations through novel drug delivery
systems. IGI Global; 2021. p. 1–42.
66. Gaucher G, Dufresne M- H, Sant VP, Kang N, Maysinger D, Leroux J- C. Block copolymer micelles:
Preparation, characterization and application in drug delivery. Journal of Controlled Release.
2005;109(1–3):169–88.
67. Xing H, Wang H, Wu B, Zhang X. Lipid nanoparticles for the delivery of active natural medicines.
Current Pharmaceutical Design. 2018;23(43):6705–13.
68. Muchow M, Maincent P, Müller RH. Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®)
for Oral Drug Delivery. Drug Development and Industrial Pharmacy. 2008;34(12):1394–405.
69. Andrade LM, De Fátima Reis C, Maione- Silva L, Anjos JLV, Alonso A, Serpa RC, et al. Impact of lipid
dynamic behavior on physical stability, in vitro release and skin permeation of genistein- loaded lipid
nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics. 2014;88(1):40–7.
70. Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: Versatile oral delivery vehicle.
Future Science OA. 2016;2(3):135.
71. Neslihan Gursoy R, Benita S. Self- emulsifying drug delivery systems (SEDDS) for improved oral deliv-
ery of lipophilic drugs. Biomedicine & Pharmacotherapy. 2004;58(3):173–82.
72. Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. International Journal of
Pharmaceutical Sciences Review and Research. 2010;5(1):41–51.
73. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. Journal of
Pharmaceutical Sciences. 1971;60(9):1281–302.
74. Yousaf AM, Malik UR, Shahzad Y, Mahmood T, Hussain T. Silymarin- laden PVP- PEG polymeric com-
posite for enhanced aqueous solubility and dissolution rate: Preparation and in vitro characterization.
Journal of Pharmaceutical Analysis. 2019;9(1):34–9.

Enhanced Bioavailability of Herbal Extracts using Nanocarriers 285
75. Gupta T, Singh J, Kaur S, Sandhu S, Singh G, Kaur IP. Enhancing bioavailability and stability of curcumin
using solid lipid nanoparticles (CLEN): A covenant for its effectiveness. Frontiers in Bioengineering and
Biotechnology. 2020;879.
76. Harwansh RK, Deshmukh R, Rahman MA. Nanoemulsion: Promising nanocarrier system for delivery of
herbal bioactives. Journal of Drug Delivery Science and Technology. 2019;51:224–33.
77. Saleh A, Akkus-Dagdeviren ZB, Haddadzadegan S, Wibel R, Bernkop- Schnürch A. Peptide antibiotic–
polyphosphate nanoparticles: A promising strategy to overcome the enzymatic and mucus barrier of the
intestine. Biomacromolecules. 2023;24(6):2587–95.
78. Bilia AR, Bergonzi MC, Guccione C, Manconi M, Fadda AM, Sinico C. Vesicles and micelles: Two
versatile vectors for the delivery of natural products. Journal of Drug Delivery Science and Technology.
2016;32:241–55.
79. Bergonzi MC, Isacchi B, Bilia AR. Octanoyl- 6–O- ascorbic acid: An efcient antioxidant with potent
solubilising properties The case of active constituents from Saint John’s wort. Journal of Drug Delivery
Science and Technology. 2013;23(5):505–9.
80. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavail-
ability of curcumin. Molecular Nutrition & Food Research. 2011;55(3):495–503.
81. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle- based
drug and gene delivery. Advanced Drug Delivery Reviews. 2016;99:28–51.
82. Misra SK, Pathak K. Targeted drug delivery approaches for the management of tumors. Tumor Discovery.
2023;2(3):1356.
83. Chakraborty G, Meher M, Dash S, Rout RN, Pradhan S, Sahoo D. Strategies for targeted delivery via
structurally variant polymeric nanocarriers. ChemistrySelect. 2023;8(29):e202301626.
84. Zeeshan F, Dua K. Pharmacokinetics and pharmacodynamics of the advanced drug delivery systems.
Elsevier; 2020. p. 551–71.
85. McDonald TO, Giardiello M, Martin P, Siccardi M, Liptrott NJ, Smith D, et al. Antiretroviral solid drug
nanoparticles with enhanced oral bioavailability: Production, characterization, and in vitro–in vivo correlation. Advanced Healthcare Materials. 2014;3(3):400–11.
86. Le H, Karakasyan C, Jouenne T, Le Cerf D, Dé E. Application of polymeric nanocarriers for enhanc-
ing the bioavailability of antibiotics at the target site and overcoming antimicrobial resistance. Applied
Sciences. 2021;11(22):10695.
87. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid- based nanocarriers.
Journal of Controlled Release. 2012;163(1):34–45.
88. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The promise of nanotechnology
in personalized medicine. Journal of Personalized Medicine. 2022;12(5):673.
89. Rombolà L, Scuteri D, Marilisa S, Watanabe C, Morrone LA, Bagetta G, et al. Pharmacokinetic interac-
tions between herbal medicines and drugs: Their mechanisms and clinical relevance. Life. 2020;10(7):106.
90. Hassen G, Belete G, Carrera KG, Iriowen RO, Araya H, Alemu T, et al. Clinical implications of herbal
supplements in conventional medical practice: A US perspective. Cureus. 2022;14(7), e26893.
91. Chavda VP, Nalla LV, Balar P, Bezbaruah R, Apostolopoulos V, Singla RK, et al. Advanced phytochemical-
based nanocarrier systems for the treatment of breast cancer. Cancers. 2023;15(4):1023.
92. Alam MK. Nanocarrier- based drug delivery systems using microuidic- assisted techniques. Advanced
NanoBiomed Research. 2023;3(11):2300041.
93. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery sys-
tems: Characterization, limitations, future perspectives and implementation of articial intelligence.
Pharmaceutics. 2022;14(4):883.
94. Salih WA, Al- Taie AA. Strategies of nanocarrier- based therapeutic drug delivery. Al- Nahrain Journal for
Engineering Sciences. 2023;26(4):365–73.
95. Kumar R. Nanotechnology in herbal medicine: Challenges and future perspectives. Nanotechnology in
Herbal Medicine: Elsevier; 2023. p. 515–48.
96. Setia A, Vallamkonda B, Challa RR, Mehata AK, Badgujar P, Muthu MS. Herbal theranostics: Controlled,
targeted delivery and imaging of herbal molecules. Nanotheranostics. 2024;8(3):344.
97. Yadav D, Suri S, Choudhary AA, Sikender M, Hemant B, Beg N. Novel approach: Herbal remedies and
natural products in pharmaceutical science as nano drug delivery systems. Int J Pharm Tech. 2011;3(3):
3092–116.

286 Herbal Pharmacopeia
98. Sharma A, Mitkare S, Moon R. Multicomponent herbal therapy: A review. International Journal of
Pharmaceutical Sciences Review and Research 2011;6:185–7.
99. Zhang J- F, Hou S- X, Liu H- L. Comparison of preparing two polylactide nanoparticles loaded lipophilic
anti- cancer herb drug by nanoprecipitation method. Zhongguo Zhong yao za zhi= Zhongguo Zhongyao
Zazhi= China Journal of Chinese Materia Medica. 2007;32(4):303–6.
100. Li Y, Dong L, Jia A, Chang X, Xue H. Preparation and characterization of solid lipid nanoparticles loaded
traditional Chinese medicine. International Journal of Biological Macromolecules. 2006;38(3–5):296–9.
101. Ansari S, Islam F, Sameem M. Inuence of nanotechnology on herbal drugs: A Review. Journal of
Advanced Pharmaceutical Technology & Research. 2012;3(3):142–6.
102. Shah N, Kumari M, Sadhu P, Talele C, Rajput HS, Sapra R. Nano- herbal innovations: Precision in thera-
peutic delivery. Journal of Advanced Zoology. 2024;45(1), 576–581.

Herbal Medicine and
13
Neurological Diseases
Sunil Kumar Kadiri and Prashant Tiwari
Department of Pharmacology, College of Pharmaceutical Sciences,
Dayananda Sagar University, Bengaluru, India
Samaresh Pal Roy
Department of Pharmacology, Sardar Patel College of Pharmacy,
Vidyanagar, Gujarat, India
Suchismita Bhowmik
Department of Community Health Nursing, Manikaka Topawala Institute
of Nursing, Charotar University of Science and Technology, Changa,
Gujarat, India
13.1 INTRODUCTION TO HERBAL MEDICINE AND NEUROLOGICAL DISEASES
Herbal medicine has been traditionally utilized for centuries across diverse cultures to address a
wide assortment of health conditions [1]. The employment of plants and plant- derived substances
has coevolved alongside conventional medicine, offering choice or complementary alternatives for
managing diseases, like those impacting the neurological system. Neurological afictions encompass an expansive spectrum of disorders inuencing the brain, spinal cord, and peripheral nerves
[2–4]. These circumstances can vary from neurodegenerative maladies such as Alzheimer’s and
Parkinson’s to neurological issues – for example epilepsy, migraines, and multiple sclerosis [5].
Standard treatments regularly involve pharmaceuticals targeting symptoms or slowing the progression of these diseases. Nevertheless, these treatments may come with side effects, leading numerous
patients and healthcare providers to explore herbal remedies as supplementary or substitute therapies
[6–8]. Herbs such as Ginkgo biloba, St. John’s Wort, and Valerian root have been researched for their
potential neuroprotective impacts and their ability to improve cognitive function, mood, and sleep.
Ginkgo biloba, for instance, is believed to enhance cognitive function by boosting blood circulation
in the brain, while St. John’s Wort is commonly utilized for its antidepressant impacts. The therapeutic possibility of herbal medicine in neurological diseases lies in the intricate interplay of various active substances found in plants. These compounds may offer antioxidant, anti- inammatory,
and neuroprotective consequences, which are crucial in managing the oxidative stress and swelling
that are frequently related to neurological conditions [9]. Despite the promising impacts of herbal
medicine, it is essential to approach its employment with caution. The efcacy of many herbal remedies is still under investigation, and their interactions with conventional medications are not fully
comprehended [10]. Additionally, the standardization of herbal products and the variability in their
active components pose substantial challenges to their consistent use in clinical settings.
As interest in herbal medicine continues to grow, further research is necessary to establish the
safety, efcacy, and mechanisms of action of these natural treatments in the context of neurological
diseases. Healthcare providers should be informed about the potential benets and risks of herbal
therapies to guide patients in making well- informed decisions about their treatment options [11].
287

288 Herbal Pharmacopeia
13.1.1 Overview Of Herbal Medicine
Herbal medicine, also known as phytotherapy, involves harnessing nature’s healing gifts from plants
and their extracts for therapeutic purposes. It has been practiced for millennia across diverse cultures
and remains integral to systems like Ayurveda, traditional Chinese medicine (TCM), and Native
American healing practices [12].
13.1.1.1 Key Aspects of Herbal Medicine
Plant sources provide remedies as fresh, dried, or extracted leaves, roots, owers, bark, seeds, and
fruits [13]. Active compounds confer benets through alkaloids, avonoids, terpenes, and glycosides working anti- inammatory, antimicrobial, antioxidant, and immune- modulating effects.
Herbal medicine often adopts a holistic stance to health, focusing on equilibrium of body, mind, and
spirit. It considers an individual’s overall wellness, rather than solely treating symptoms [14–18].
Commonly used herbs include: immune- bolstering Echinacea reducing cold duration; St.
John’s Wort, which has anti- depressant and mood- stabilizing actions; energy- enhancing,
cognitive- function- boosting ginseng; and anti- inammatory, antioxidant turmeric (Figure
13.1). Similarly, peppermint frequently eases digestion and headaches.
Safety and efcacy matter: while many herbs are safe with proper use, some may interact
dangerously with medications or cause side effects. Seek qualied guidance, especially
with regard to health issues or other medications. Modern integration increasingly merges
herbal medicine into mainstream care as complementary therapies alongside conventional
treatments. This stimulated scientic research into various remedies’ effectiveness and
risks. Regulation varies between designating herbal medicines as dietary supplements or
classifying some as drugs requiring stricter testing and approval [19]. Herbal medicine continues valuably blending antiquity’s wisdom with modern science for health and wellness.
13.1.2 ScOpe Of neurOlOgical diSeaSeS
Neurological diseases encompass a broad spectrum of disorders that affect the brain, spinal cord,
and peripheral nervous system. These conditions can range from common ailments like migraines
and epilepsy to more complex and debilitating diseases such as Alzheimer’s, Parkinson’s, multiple
FIGURE 13.1 Some prominent herbs with Medicinal properties.

Herbal Medicine and Neurological Diseases 289
sclerosis, and the motor neuron disease known as amyotrophic lateral sclerosis [20]. The scope of
neurological diseases is vast due to the immense complexity of the human nervous system, which
intricately controls and coordinates each and every one of the body’s innumerable functions [21].
These diseases hold the potential to impact motor skills, sensory awareness, cognition, behavior, and
autonomic functions. Genetic predispositions, environmental exposures, infectious agents, physical
traumas, or even etiologies that remain unknown – any of these triggers may underlie the origins
of specic neurological disorders [22]. Treating and managing neurological diseases frequently
demands an interdisciplinary clinical strategy, incorporating pharmaceutical interventions, physical
and occupational therapies, psychological support services, and, in some cases, surgical options.
Continual advances in scientic research serve to expand our fundamental understanding of these
conditions, leading to enhanced diagnostic techniques, rened treatment protocols, and, in a few
instances, even prospective preventative measures.
13.1.3 ratiOnale fOr explOring Herbal reMedieS
Exploring herbal remedies is a tradition rooted in humanity’s innate drive to heal itself through
natural means whenever possible. This pursuit of gentler options includes several compelling rationales [23]. The long cultural pedigree of many plants’ medical usages, as generations shared which
species soothed what suffering. That enduring ethnobotanical paper trail hints some herbs warrant
careful studies into whether tradition translates to treatment. Herbs are widely perceived as wielding
fewer potential side effects than manufactured pharmaceuticals, a quality valued by those navigating
delicate conditions or desiring delicate approaches [24–29]. Gentleness also means gentler remedies
may complement conventions where those fall short. Herbalism often sees the person, rather than
just the pathology, prioritizing overall wellness – a perspective increasingly popular as prevention,
not just reaction, gains favor. Treating the whole being aligns with this holistic health model.
Bacteria’s accelerating resistance and the downsides of long- term medication lead to an urgent
need for alternatives. Nature’s plants, whose compounds work in complex concert, may offer novel
ways to manage persistent infections and persistent patients [30].
Modern technology enables scientists to extract and analyze the active elements of herbs, providing valuable insights that can be applied to other elds such as medicine research and supplement
formulation. This scientic validation has the potential to greatly enhance accessibility.
Herbal medicines are often more economically efcient and environmentally sensitive, which is
particularly important when infrastructure is unreliable. Botanical medicine can be a crucial solution
for populations that have limited access to healthcare services [31–33].
Although herbalism shows promise, it is crucial to prioritize rigorous study in order to establish
the safety, effectiveness, and consistent benets of medicines.
13.2 NEUROPROTECTIVE EFFECTS OF HERBAL COMPOUNDS
Neuroprotective properties of herbal compounds pertain to the capacity of specic molecules produced from plants to shield brain cells (neurons) against harm, deterioration, or demise [34]. The
impact of these consequences is highly important in the context of neurological disorders such
as Alzheimer’s, Parkinson’s, stroke, and multiple sclerosis. In these conditions, oxidative stress,
inammation, and excitotoxicity play a crucial role in causing damage to neurons.
13.2.1 MecHaniSMS Of neurOprOtectiOn
13.2.1.1 Antioxidant Activity
Compounds abundant in antioxidants, such as curcumin from turmeric and the avonoids found in
an assortment of fruits and vegetables, have demonstrated an ability to shelter neurons by scavenging
damaging free radicals, which balances oxidative stress, a principal factor in neurodegeneration. Many
plant extracts contain antioxidants that counteract free radicals and decrease oxidative stress [35–39].

290 Herbal Pharmacopeia
FIGURE 13.2 Potential mechanism of action of medicinal herbs.
13.2.1.2 Anti- inammatory Properties
Persistent irritation within the mind is a hallmark of many neurological issues. Certain herbal
extracts, including resveratrol present in grapes and ginsenosides discovered in ginseng, exhibit
anti- inammatory results through inhibiting the manufacturing of pro- inammatory cytokines and
modulating immune responses, thereby decreasing neuronal injury [40]. Herbal compounds have
also been proven to curb inammation in the mind, a hallmark of neurological issues (Figure 13.2).
13.2.1.3 Inhibition of Excitotoxicity
Excitotoxicity occurs when neurons are excessively stimulated by neurotransmitters such as glutamate, leading to cellular damage and death. Certain herbs include chemicals that can help control
neurotransmitter levels, thereby reducing excitotoxic damage. For instance, Ginkgo biloba has components that help regulate neurotransmitter levels [41].
13.2.1.4 Enhancement of Neurogenesis and Synaptic Plasticity
Herbal extracts with positive effects promote the formation of new neurons, a process called neurogenesis, and enhance synaptic plasticity, which is crucial for learning, memory, and overall brain
function. An example is the presence of bacosides in Bacopa monnieri, which have been examined
for their capacity to improve cognitive functions by promoting neurogenesis and synaptic communication [42–49].
13.2.1.5 Mitochondrial Protection
Neurodegenerative disorders have a particular impact on mitochondria, which are the cellular
powerhouses responsible for generating energy. Research indicates that herbal substances such as

Herbal Medicine and Neurological Diseases 291
berberine found in goldenseal and quercetin found in various fruits and vegetables have the capacity
to enhance mitochondrial activity and protect against energy deciencies in neurons.
13.2.2 rOle Of Oxidative StreSS in neurOlOgical diSeaSeS
Oxidative stress is a pivotal factor in the initiation and advancement of several neurological disorders. It arises from a disparity between the generation of reactive oxygen species (ROS) and the
body’s capacity to counteract them with antioxidants [50]. This imbalance results in the buildup of
reactive oxygen species (ROS), which can harm cellular structures, including DNA, proteins, and
lipids. Neurons, in particular, are prone to oxidative damage because of their high oxygen consumption and inadequate antioxidant defenses.
13.2.2.1 Essential Components of Oxidative Stress in Neurological Disorders
13.2.2.1.1 Impaired Functioning of Mitochondria
Neurons are highly dependent on mitochondria for their energy needs. Oxidative stress- induced
damage to mitochondria results in decreased energy production and further amplies the creation
of reactive oxygen species (ROS), establishing a detrimental loop of damage that contributes to
dementia. Oxidative stress has the potential to induce genetic mutations in DNA and alter proteins,
thereby interfering with their regular functioning. This damage might result in cellular impairment
and demise, hence exacerbating the advancement of neurological disorders [51–54]. Lipid peroxidation occurs when ROS target and damage lipids found in cell membranes, especially in the brain
where there is a high concentration of polyunsaturated fatty acids. Lipid peroxidation is the process
that causes damage to the cell membrane, resulting in the loss of cell integrity and ultimately leading
to the death of neurons.
13.2.2.1.2 Neurological Disorders Linked to Oxidative Stress
Alzheimer’s disease: Oxidative stress has a role in the development of beta- amyloid plaques and tau
tangles, which are characteristic features of Alzheimer’s disease and are linked to the loss of neurons
and deterioration in cognitive function.
Parkinson's disease: Oxidative stress contributes to the deterioration of dopaminergic neurons
in the substantia nigra in Parkinson’s disease, primarily as a result of the oxidative breakdown of dopamine [55].
Amyotrophic lateral sclerosis (ALS): The breakdown of motor neurons is associated with oxi-
dative stress, in which mutations in antioxidant enzymes such as superoxide dismutase 1
(SOD1) have a notable impact.
Multiple sclerosis (MS): Oxidative stress worsens inammation and demyelination in MS,
causing additional harm to neurons and advancing the disease.
Stroke: The occurrence of a stroke leads to a signicant increase in ROS due to the damage
caused by the interruption and restoration of blood ow. This surge in ROS results in substantial damage to the neurons, which worsens the severity of the injury [56].
Therapeutic implications: The comprehension of oxidative stress in neurological disorders
has generated curiosity in antioxidant treatments designed to diminish oxidative harm and
decelerate the advancement of the condition. Nevertheless, the intricate nature of oxidative stress pathways in the brain poses difculties, necessitating further research to devise
efcacious treatments.
13.2.3 anti- inflaMMatOry prOpertieS Of Herbal cOMpOundS
The varied anti- inammatory capacities of herbal substances have long been acknowledged for their
notable part in managing and forestalling diverse inammatory issues, including those impacting

292 Herbal Pharmacopeia
the sensory system [57]. These chemicals can impede irritation through different instruments, giving
a common elective or expansion to conventional anti- inammatory medications.
13.2.3.1 Anti- Inammatory Activity Systems
Suppression of pro- inammatory cytokines: Certain herbs like curcumin derived from turmeric
and resveratrol found in grapes have appeared capable of diminishing the combination of proinammatory cytokines like TNF- α, IL- 1β, and IL- 6. By suppressing these signaling particles, they
help in diminishing cellular irritation [58].
The NF- κB pathway plays a key job in controlling the inammatory reaction. A few herbal sub-
stances, like gingerol found in ginger and epigallocatechin gallate (EGCG) from green tea, have the
capacity to block the initiation of NF- κB, bringing about a decrease in the articulation of qualities
related with swelling.
Antioxidant effects: Oxidative pressure and aggravation are rmly intertwined, as responsive
oxygen types (ROS) frequently start inammatory pathways. Herbal substances containing intense antioxidants, like quercetin present in different natural products and vegetables and avonoids, help in diminishing oxidative pressure, subsequently diminishing
irritation.
Suppression of COX and LOX enzymes: The inammatory process is impacted by the creation
of pro- inammatory mediators, for example, prostaglandins and leukotrienes, which are
created by enzymes called cyclooxygenase (COX) and lipoxygenase (LOX) [59]. Blends
like boswellic corrosive, obtained from frankincense, and salicin, extracted from willow
bark, have the capacity to impede these enzymes, along these lines diminishing irritation.
Immune system modulation: Certain herbs have an inherent ability to govern the immune reac-
tion by upholding equilibrium between pro- and anti- inammatory signals. For example,
ginsenosides derived from ginseng and complex sugars obtained from fungi such as reishi
have the potential to better immunological regulation, thereby facilitating a more balanced
inammatory feedback.
13.2.3.2 Uses and Advantages
Chronic Inammatory Illnesses: Herbal anti- inammatory agents are commonly applied to
manage persistent inammatory conditions – for example, rheumatoid arthritis, inammatory bowel disease, and asthma [60–64]. They have the possibility to diminish the necessity
for the extended application of standard anti- inammatory medications, which can result
in notable adverse effects.
Neurological Disorders: Inammation plays a crucial part in neurodegenerative diseases
such as Alzheimer’s, Parkinson’s, and multiple sclerosis. Herbal ingredients with antiinammatory qualities own the ability to retard the progression of illnesses and provide relief
from symptoms. Herbal compounds are often employed to treat inammatory skin disorders, such as eczema, psoriasis, and dermatitis, due to their relaxing and anti- inammatory
properties.
Cardiovascular Health: Enduring inammation notably contributes to the evolution of car-
diovascular sicknesses. Herbal ingredients possess the ability to mitigate inammation in
blood vessels, hence decreasing the prospect of atherosclerosis and related ailments.
The therapeutic potential of herbal components is substantiated by both ancestral usage and modern
scientic investigation, owing to their anti- inammatory traits. Although they have possible healing
benets, it is crucial to approach their application with an appreciation of suitable dosage, potential
interactions with other medications, and the necessity for extra analysis to substantiate effectiveness
and safety in specic circumstances.

Herbal Medicine and Neurological Diseases 293
13.2.4 regulatiOn Of neurOnal apOptOSiS by Herbal reMedieS
Promising research has also been carried out on the ability of certain herbal remedies to regulate
neuronal apoptosis (programmed cell death) in respect of neurodegenerative diseases where excessive or dysregulated apoptosis plays a part in the attrition of neurons [65]. Indeed, some herbal compounds have been found to positively modulate apoptotic pathways, leading to neuronal survival,
and may be useful for promoting brain health (Figure 13.3).
For example, herbal compounds such as curcumin (from turmeric) and ginsenosides (ginseng)
are found to inhibit pro- apoptotic proteins such as Bax, caspases, cytochrome c which, upon inhibition, reduce the markers of the apoptosis pathway, and hence prohibiting triggering an event to
prevent the death of neurons.
Activation of Anti- apoptotic Pathways: Some herbal remedies increase the levels of anti-
apoptotic proteins such as Bcl- 2 (together with decreasing, for example, Bak), which stabilize mitochondria and inhibit apoptosis signals. Compounds like resveratrol (found in
grapes) and epigallocatechin gallate, or EGCG for short (from green tea), have been shown
to turn on these protective pathways.
Reducing Oxidative Stress: In the brain, one of the main stimulants for neuronal apoptosis is
oxidative stress. The strong antioxidant properties of some herbal compounds like quercetin, avonoids neutralize the ROS and thus reduced oxidative damage preventing apoptosis.
Modulation of Signaling Pathways: Herbal compounds can modulate important signaling
pathways responsible for apoptosis, e.g., MAPK/ERK pathway, PI3/Akt and JNK. For
example, various phytochemicals (baicalin from Sc), and honokiol (from Mo) were shown
to act on this pathway protecting neurons by activation of survival genes and preventing the
induction of death cell osteosis [66–68].
FIGURE 13.3 Mechanisms involved in the regulation of neuronal apoptosis by herbal medicines.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
